Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all synonyms
Human Monoclonal EPH Receptor A5 Primary Antibody for ELISA, WB - ABIN969102
Yang, Ramnath, Moysich, Asch, Swede, Alrawi, Huberman, Geradts, Brooks, Tan: Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer. in BMC cancer 2006
Show all 2 Pubmed References
Cow (Bovine) Polyclonal EPH Receptor A5 Primary Antibody for WB - ABIN2787691
Mehrle, Rosenfelder, Schupp, del Val, Arlt, Hahne, Bechtel, Simpson, Hofmann, Hide, Glatting, Huber, Pepperkok, Poustka, Wiemann: The LIFEdb database in 2006. in Nucleic acids research 2005
Human Monoclonal EPH Receptor A5 Primary Antibody for CyTOF, FACS - ABIN4900429
Akaneya, Sohya, Kitamura, Kimura, Washburn, Zhou, Ninan, Tsumoto, Ziff: Ephrin-A5 and EphA5 interaction induces synaptogenesis during early hippocampal development. in PLoS ONE 2010
Gene-based analysis identified EPHA6 (show Epha6 Antibodies) as the gene most significantly associated with paclitaxel-induced neuropathy...This first study sequencing EPHA genes revealed that low-frequency variants in EPHA6 (show Epha6 Antibodies), EPHA5, and EPHA8 (show EPHA8 Antibodies) contribute to the susceptibility to paclitaxel-induced neuropathy
Our data indicate that EphA5 receptor may be a tumor suppressor in colorectal carcinoma and it may be a new therapeutic target for colorectal carcinoma.
EphA5 protein was negatively (0) or weakly (1+) expressed in 48 of 78 (61.5%), moderately (2+) expressed in 15 of 78 (19.2%) and strongly (3+) expressed in 15 of 78 (19.2%) tumour samples of clear cell renal cell carcinoma (show MOK Antibodies) (ccRCC). Decreased expression of EphA5 was detected more often in females than in males
the interactions of EphA5/ephrinA5 and/or EphA7/ephrinA5 between HSPCs and BMSCs, independently and cooperatively, play a role in HSPC colony formation through the upregulation of GM-CSFR. Furthermore, the adhesion/migration of HSPCs appears to be mediated in part through the activation of Rac1.
Our results show that EphA5 may be a potential biomarker for distinguishing high-and low-grade ovarian serous carcinoma and a potential prognostic marker.
Our study provides evidence that EphA5 is a potential target for epigenetic silencing in primary prostate cancer and is a potentially valuable prognosis predictor and thereapeutic marker for prostate cancer.
demonstrate that a new monoclonal antibody against human EphA5 sensitized lung cancer cells and human lung cancer xenografts to radiotherapy and significantly prolonged survival, thus suggesting the likelihood of translational applications
unbound EphA5 LBD appears to comprise an ensemble of open conformations that have only small variations over the loops and appear ready to bind ephrin-A ligands
These results indicate that EphA5 may be a negative regulator of bone formation.
Insertional translocation leading to a 4q13 duplication including the EPHA5 gene is associated with attention-deficit. hyperactivity disorder
Observations suggest that ephrin-A5 (show EFNA5 Antibodies) plays a key role in the development and/or function of neural pathways mediating mouse maternal care and anxiety.
methylation of only six of 98 CpG dinucleotides within the EphA5 promoter blocks its transactivation by KLF16 but enables transactivation by KLF2 and KLF15.
We examined the roles of ephrin-A2 (show EFNA2 Antibodies) and ephrin-A5 (show EFNA5 Antibodies) signaling in contralateral targeting and topographic ordering in the ventral cochlear nucleus
ephrinA5/EphA3 (show EPHA3 Antibodies) triggers proteolysis of the neural cell adhesion molecule (NCAM (show NCAM1 Antibodies)) by the metalloprotease (show ADAMTS7 Antibodies) a disintegrin and metalloprotease (ADAM)10 (show ADAM10 Antibodies) to promote growth cone collapse in neurons from mouse neocortex.
Results demonstrated that the ephrinA5-EphA4 (show EPHA4 Antibodies)/EphA5 system plays an important role in the direct pathway-dependent regulation of the SNr in cocaine responses and would provide valuable therapeutic targets of cocaine addiction.
ephrin-A5 (show EFNA5 Antibodies) and EphA5 signals play a necessary, activity-independent role in the initiation of the early phases of synaptogenesis
mistargeting hippocampal axons by expression of a truncated eph (show EPHA1 Antibodies)-A5 receptor
Neocortical expression of Epha5 during development is altered in the absence of cellular contacts or thalamocortical connections, suggesting that epha5 is plastically regulated.
Ephrin A5 (show EFNA5 Antibodies) receptor in the thalamus and ephrin A5 (show EFNA5 Antibodies) in the cerebral cortex control intra-areal topographic mapping of thalamocortical axons.
Gene disruption of mouse EphA5 reduced in vitro responsiveness of temporal axons to posterior target membranes. It also caused map abnormalities in vivo, with temporal axons shifted posteriorly and nasal axons anteriorly
This gene belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. EPH and EPH-related receptors have been implicated in mediating developmental events, particularly in the nervous system. Receptors in the EPH subfamily typically have a single kinase domain and an extracellular region containing a Cys-rich domain and 2 fibronectin type III repeats. The ephrin receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. Two transcript variants encoding different isoforms have been found for this gene.
EPH homology kinase 1
, EPH-like kinase 7
, brain-specific kinase
, ephrin type-A receptor 5
, receptor protein-tyrosine kinase HEK7
, tyrosine-protein kinase receptor EHK-1
, ephrin receptor EphA5
, EPH receptor A5
, ephrin type-A receptor 5-like
, eck-like sequence 1
, receptor-type protein-tyrosine kinase